AOD-9604

§01Summary

AOD-9604 is a synthetic peptide derived from the C-terminal region of human growth hormone, specifically designed to target fat metabolism without the growth-promoting or blood sugar-altering effects associated with full-length growth hormone. The compound was developed primarily as a potential treatment for obesity, with its mechanism focused on stimulating the breakdown of fat tissue and inhibiting the formation of new fat cells. Early clinical development activity, including Phase IIa trials, was documented in the early-to-mid 2000s³, and AOD-9604 appeared in clinical trial registries as an active investigational compound during that period^1,2. The peptide attracted attention in sports and athletic communities, leading to its appearance in anti-doping contexts and regulatory discussions⁴. The peer-reviewed human evidence base for AOD-9604 is currently developing, with the existing published literature consisting primarily of clinical trial listings and pipeline reports rather than primary outcomes data. Research into its lipolytic properties and potential metabolic applications represents an active area of scientific interest.

This is the layperson summary. Mechanism, dosing, the evidence base, and the published literature are in the sections below — every claim links to its source.

§02In depth

AOD-9604 is a 15-amino acid synthetic peptide corresponding to residues 177–191 of the C-terminal domain of human growth hormone (hGH), with an additional tyrosine residue added at the N-terminus to facilitate radiolabeling and pharmacokinetic study. This fragment was engineered to preserve the lipolytic (fat-breakdown) activity attributed to the C-terminal region of hGH while eliminating the anabolic, somatogenic, and insulin-desensitizing properties associated with full-length growth hormone signaling through the GH receptor.

The proposed mechanism of action involves activation of beta-3 adrenergic receptors, which are expressed on adipocytes (fat cells) and play a central role in regulating lipolysis and thermogenesis. Stimulation of this receptor subtype promotes the breakdown of stored triglycerides into free fatty acids and glycerol, facilitating their mobilization for energy use. AOD-9604 has also been reported in preclinical contexts to inhibit lipogenesis — the de novo synthesis of fat — potentially through effects on key regulatory enzymes in the lipogenic pathway. This dual action on fat catabolism and anabolism formed the rationale for its development as an anti-obesity agent³.

Importantly, AOD-9604 does not appear to engage the canonical GH receptor-IGF-1 signaling axis that mediates the growth-promoting and diabetogenic effects of full-length hGH. This pharmacological selectivity was a central design objective, distinguishing it from earlier growth hormone-based therapeutic approaches. The peptide's small molecular size places it in the sub-2 kDa range, which has pharmacokinetic implications for oral bioavailability and renal clearance, and has been relevant to its detection in anti-doping analytical methodologies.

The compound's categorization and mechanism have at times been misrepresented in non-scientific contexts — including an erroneous characterization as an antidepressant in journalistic coverage⁴ — which does not align with its established pharmacological profile as a lipolytic peptide fragment. The precise receptor binding affinities, human pharmacokinetic parameters including half-life and bioavailability across administration routes, and downstream metabolic effects in human subjects are areas where the peer-reviewed evidence base is continuing to develop.

§04Evidence & efficacy

No primary human efficacy data are reported in any of the studies included in this analysis. AOD-9604 was documented as being in Phase IIa clinical development for obesity as of early 2002³ and appeared in active clinical trial registries through at least 2005^1,2, indicating that formal efficacy evaluation was underway during that period. However, none of the identified sources report outcomes, endpoints, or results from those or any subsequent trials. The compound's presence in anti-doping literature and sports-related commentary⁴ reflects its profile as an investigational agent, but contributes no efficacy evidence. Human efficacy data for AOD-9604 across its investigated indications is actively emerging.

§05Safety

No primary human safety data — including adverse event profiles, tolerability findings, contraindications, or drug interaction data — are reported in any of the studies included in this analysis. The available publications are limited to clinical trial directory listings^1,2, a brief pipeline development note³, and non-peer-reviewed commentary⁴. None of these sources contain original safety observations or clinical adverse event reporting for AOD-9604. The broader scientific literature touching on AOD-9604 in doping detection contexts does not contribute safety outcome data. Human safety characterization of AOD-9604 is an area of active clinical investigation.

§06History

AOD-9604 was developed by Metabolic Pharmaceuticals, an Australian biotechnology company, as a synthetic analogue of the C-terminal fragment of human growth hormone. The compound emerged from research efforts in the 1990s aimed at isolating and leveraging the fat-metabolizing properties of hGH without replicating its systemic growth and metabolic side effects. The core scientific rationale was that the lipolytic activity of hGH could be localized to a specific peptide domain and exploited therapeutically for obesity.

By early 2002, Metabolic Pharmaceuticals had advanced AOD-9604 into Phase IIa clinical trials for obesity³, representing a significant milestone in the compound's development trajectory. The peptide was listed in multiple international clinical trial registries and drug development directories through at least 2005^1,2, reflecting sustained industry interest during that period. Later in its history, AOD-9604 entered public and regulatory attention in Australia due to its use by athletes and sports organizations, generating controversy around its status as a non-approved substance and its classification under anti-doping frameworks⁴. This exposure introduced the compound to a broader audience beyond clinical research circles. Its presence in anti-doping analytical literature reflects the development of detection methodologies tracking its use. The compound's clinical development history and current regulatory and research status represent an evolving landscape.

§07References

• [1]Gateways to clinical trialsBayés M; Rabasseda X; Prous JR · Methods and findings in experimental and clinical pharmacology · 2005 ↗
• [2]Gateways to clinical trialsBayés M; Rabasseda X; Prous JR · Methods and findings in experimental and clinical pharmacology · 2003 ↗
• [3]AOD-9604 MetabolicWilding J · Current opinion in investigational drugs (London, England : 2000) · 2004 ↗
• [4]AOD-9604: The anti-depressant making Australian sport a very unhappy placeAmy Jennings · 2013